143 related articles for article (PubMed ID: 37357301)
1. 'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Dickson SP; Wessels AM; Dowsett SA; Mallinckrodt C; Sparks JD; Chatterjee S; Hendrix S
J Prev Alzheimers Dis; 2023; 10(3):595-599. PubMed ID: 37357301
[TBL] [Abstract][Full Text] [Related]
2. Donanemab in Early Alzheimer's Disease.
Mintun MA; Lo AC; Duggan Evans C; Wessels AM; Ardayfio PA; Andersen SW; Shcherbinin S; Sparks J; Sims JR; Brys M; Apostolova LG; Salloway SP; Skovronsky DM
N Engl J Med; 2021 May; 384(18):1691-1704. PubMed ID: 33720637
[TBL] [Abstract][Full Text] [Related]
3. Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Wessels AM; Dennehy EB; Dowsett SA; Dickson SP; Hendrix SB
Neurol Clin Pract; 2023 Apr; 13(2):e200127. PubMed ID: 36891463
[TBL] [Abstract][Full Text] [Related]
4. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial.
Sato S; Hatakeyama N; Fujikoshi S; Katayama S; Katagiri H; Sims JR
Neurol Ther; 2024 Jun; 13(3):677-695. PubMed ID: 38581616
[TBL] [Abstract][Full Text] [Related]
5. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR; Zimmer JA; Evans CD; Lu M; Ardayfio P; Sparks J; Wessels AM; Shcherbinin S; Wang H; Monkul Nery ES; Collins EC; Solomon P; Salloway S; Apostolova LG; Hansson O; Ritchie C; Brooks DA; Mintun M; Skovronsky DM;
JAMA; 2023 Aug; 330(6):512-527. PubMed ID: 37459141
[TBL] [Abstract][Full Text] [Related]
6. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
7. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA
JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300
[TBL] [Abstract][Full Text] [Related]
8. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.
Shcherbinin S; Evans CD; Lu M; Andersen SW; Pontecorvo MJ; Willis BA; Gueorguieva I; Hauck PM; Brooks DA; Mintun MA; Sims JR
JAMA Neurol; 2022 Oct; 79(10):1015-1024. PubMed ID: 36094645
[TBL] [Abstract][Full Text] [Related]
9. Still grasping at straws: donanemab in Alzheimer's disease.
Doggrell SA
Expert Opin Investig Drugs; 2021 Aug; 30(8):797-801. PubMed ID: 34162295
[TBL] [Abstract][Full Text] [Related]
10. The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial.
Wessels AM; Andersen SW; Dowsett SA; Siemers ER
J Prev Alzheimers Dis; 2018; 5(2):134-136. PubMed ID: 29616706
[TBL] [Abstract][Full Text] [Related]
11. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
Wessels AM; Dowsett SA; Sims JR
J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
[TBL] [Abstract][Full Text] [Related]
12. Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.
Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Shcherbinin S; Ardayfio P; Mullins GR; Sims JR
Clin Pharmacol Ther; 2023 Jun; 113(6):1258-1267. PubMed ID: 36805552
[TBL] [Abstract][Full Text] [Related]
13. Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease.
Jönsson L; Ivkovic M; Atri A; Handels R; Gustavsson A; Hahn-Pedersen JH; León T; Lilja M; Gundgaard J; Raket LL
Alzheimers Res Ther; 2024 Feb; 16(1):48. PubMed ID: 38424559
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
[TBL] [Abstract][Full Text] [Related]
15. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
16. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
[TBL] [Abstract][Full Text] [Related]
17. Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Gueorguieva I; Willis BA; Chua L; Chow K; Ernest CS; Wang J; Shcherbinin S; Sims JR; Chigutsa E
Alzheimers Dement (N Y); 2023; 9(2):e12404. PubMed ID: 37388759
[TBL] [Abstract][Full Text] [Related]
18. Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.
Wessels AM; Belger M; Johnston JA; Yu Y; Rentz DM; Dowsett SA; Chandler J
J Alzheimers Dis; 2022; 88(2):577-588. PubMed ID: 35694928
[TBL] [Abstract][Full Text] [Related]
19. Disease progression model using the integrated Alzheimer's Disease Rating Scale.
Gueorguieva I; Chua L; Willis BA; Sims JR; Wessels AM
Alzheimers Dement; 2023 Jun; 19(6):2253-2264. PubMed ID: 36450003
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]